This report provides an in-depth analysis of Zepp Health Corporation's (NYSE: ZEPP) Q3-2024 performance, highlighting a 4% QoQ revenue increase but a 49% YoY decline due to lower unit sales and product discontinuations. The report examines the launch of the T-Rex 3 smartwatch, supply chain constraints, and Zepp's competitive positioning in the global smartwatch market. It also discusses management's optimistic Q4 guidance, industry trends, and the valuation discrepancy between Zepp's market cap ...
Zepp Health Corporation (NYSE: ZEPP) experienced a significant revenue decline in Q2-2024, down 56% year-over-year, missing estimates due to lower-than-expected unit sales and the discontinuation of low-margin products. Despite the drop, cost-cutting measures led to an improvement in EBITDA, though it remained negative. The global smartwatch market also saw a 9% decline in shipments, impacting Zepp’s performance. However, the company is optimistic about a recovery in the second half of the year,...
Zepp Health specializes in smart wearables, providing advanced health tracking and fitness monitoring solutions. Despite a challenging Q1 2024, Zepp Health's strategic decisions and commitment to innovation are setting the stage for a promising year ahead. - Q1 2024 Performance: Revenue down 55% YoY, missing estimates by 7% due to lower unit sales. - Strategic Moves: Halted production of low-margin products, boosting gross profit for self-branded units by 33% YoY. - Market Position: Maintained ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.